GLP-1, GIP, glucagon and amylin name different signaling systems, not four interchangeable versions of one weight-loss peptide. Current research uses single-target analogues, engineered coagonists and combinations of separate molecules. To compare them, identify the molecular design and then the human experiment. Receptor count alone cannot rank weight loss, tolerability or a disease-specific outcome.

Compare pathways before comparing percentages

Metabolic peptide discussions often mix receptor mechanisms, trial results and product names. A useful comparison separates those layers. A receptor label identifies a biological target; a clinical trial measures an outcome in a defined population; a product record establishes a particular formulation and regulatory context. More receptor targets do not automatically mean a better result for every person or a more favorable balance of benefit and harm.

A pathway map

Scroll horizontally to read all columns.

PeptidePathway described in the cited researchImportant distinction
Liraglutide / semaglutideGLP-1 receptorSeparate molecules and product-specific evidence
TirzepatideGIP and GLP-1 receptorsNot the same pairing as GLP-1/glucagon
Survodutide / mazdutideGLP-1 and glucagon receptorsShared targets do not establish equivalence
RetatrutideGIP, GLP-1 and glucagon receptorsTriple-target identity is not a comparative efficacy result
CagrilintideAmylin-related pathwayCagriSema includes semaglutide as a second component

Single molecule versus combination

A multi-receptor agonist and a combination of two compounds are different designs. Tirzepatide is discussed as one molecular intervention with two receptor targets. CagriSema combines cagrilintide and semaglutide. If a trial measures the combination, the complete outcome cannot be assigned to either component alone unless the design and analysis allow that conclusion. This distinction also prevents a studied combination from being treated as permission to assemble an untested mixture.

Which population was enrolled?

Studies in people with type 2 diabetes ask a different question from studies that exclude diabetes. Eligibility criteria, baseline body mass, concurrent treatment and prior exposure may influence both outcomes and tolerability. Geographic setting and clinical practice also affect applicability. A comparison should show these features beside the result rather than hide them behind a single headline percentage.

Why duration and estimands matter

A 24-week result and a 76-week result do not represent the same observation period. Also inspect how the study handled discontinuation or rescue treatment. A treatment-policy or treatment-regimen analysis may include outcomes regardless of whether people continued the assigned intervention. An analysis focused on continued treatment answers another question. Comparing the two as if they were the same can exaggerate apparent differences between compounds.

Safety is not a footnote

Read adverse events, withdrawals and missing data alongside the efficacy endpoint. A larger mean weight change does not describe the full experience of the participants. Avoid creating a safety ranking from raw adverse-event percentages across unrelated trials because collection methods and populations can differ. Where direct comparative evidence is absent, state that the comparison is indirect.

Weight, glycemia and liver histology

Body weight, HbA1c and liver histology are distinct endpoints. They may all be relevant to metabolic health, but a change in one does not automatically establish a benefit in another. The survodutide liver-disease study is a useful example: a biopsy-based endpoint needs its own interpretation and should not be replaced with a weight-loss headline.

Read a pathway map without turning it into a leaderboard

A GLP-1-related analogue and a GIP/GLP-1 coagonist differ in their receptor-related design. A glucagon/GLP-1 candidate adds another combination of activities. An amylin analogue belongs to a distinct signaling family. The map is useful for locating the hypothesis behind a study, but it does not predict the clinical balance of the finished intervention.

Even the direction of activity must be checked. An agonist and an antagonist involving the same receptor are not interchangeable descriptions. MariTide is a useful reminder that a familiar receptor name can appear within a different architecture and pharmacological strategy. Copy the source’s description rather than infer the action from a headline.

Selectivity and signaling bias add further detail when supported by appropriate assays. They remain assay-defined properties. Human efficacy and tolerability require their own measurements, so a molecular design description should not be shortened to better or safer without a relevant clinical comparison.

A coagonist and a combination are different interventions

An engineered molecule with more than one receptor activity has one defined molecular identity and exposure profile. A combination program uses separately identified components under a specified formulation and regimen. CagriSema, for example, should be read through the trial of the assigned cagrilintide–semaglutide combination, not treated as a generic name for every amylin/GLP-1 strategy.

A trial of the combination also does not validate a mixture of separately sourced research peptides. The characterized components, formulation and assigned use belong to the experiment. Reconstructing the receptor list does not reconstruct the tested product.

Compare the endpoint before comparing the number

Weight change, HbA1c change and biopsy-defined liver outcomes are different endpoints. A candidate with a favorable liver result cannot be ranked against a weight-only trial as though both measured the same benefit. The actual unit, visit and enrolled condition need to sit beside each result.

Diabetes status is another essential column. Trials in people with and without type 2 diabetes may have different eligibility, accompanying treatment and outcomes. A comparison should not select one candidate’s best result from one population and another’s result from a different population while omitting the difference.

The semaglutide–tirzepatide article examines what a direct randomized comparison can add. The retatrutide comparison explains why separate trial programs require more restraint.

What belongs beside efficacy in a useful comparison table

Record adverse events, discontinuation and the assigned escalation scheme. A weight estimate under a hypothetical continued-adherence analysis does not by itself describe the experience of everyone who started. A treatment-policy estimate may answer another question. Keep the analysis label rather than choosing whichever figure gives the clearest ranking.

Duration and source type also belong in the table. A short published phase 2 trial, a longer phase 3 report and a sponsor top-line announcement have different evidential scope. None should be disguised as a replicate of another just because the receptor targets overlap.

For research peptides, this approach makes the pathway map useful without turning it into a promise. Start with the design, locate the exact human comparison and preserve the outcome definition. If a desired ranking is not supported by that record, the useful result of the review is identifying the missing comparison.

A reliable way to read the next headline

Write down the molecule, the comparator, the population, the duration, the primary endpoint and the analysis approach. Then ask whether the headline adds a claim the paper did not test. Use the individual dossiers above for source links and the clinical endpoint guide for interpretation. This comparison organizes research; it is not a treatment-selection tool or a live global approval registry.

A comparison worksheet with a useful blank column

Create a row for each exact intervention, then record target activity, formulation, enrolled condition, endpoint and assessment visit. Add a final column called direct comparator. If that column says placebo for two different candidates, the table has not created a head-to-head comparison between them. The blank is a finding about the evidence available.

For a combination, identify whether a component arm was included. For a coagonist, identify whether the study could isolate the role of an individual receptor activity. These are different causal questions. A combination-versus-placebo result does not quantify the added value over one component, and a coagonist-versus-placebo result does not measure the isolated contribution of its extra target.

Keep the worksheet short enough to inspect. A long catalog of receptor names can make the research seem clearer while concealing mismatched trials. The few fields that define the intervention and comparison are more useful than an unsupported score for overall effectiveness.